Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Relationships between genetic polymorphisms and anticancer drug cytotoxicity vis-à-vis the NCI-60 panel.

Pharmacogenomics - 1 Sept 2006

Le Morvan Valérie, Bellott Ricardo, Moisan François, Mathoulin-Pélissier Simone, Bonnet Jacques, Robert Jacques

Abstract excerpt

INTRODUCTION: The National Cancer Institute (NCI)-60 panel consists of 60 human tumor cell lines initially established for screening thousands of molecules for antiproliferative activity. It has been powerful for deciphering the relationships between anticancer drug cytotoxicity and cell molecular characteristics. We tested its potential interest for establishing relationships between the polymorphism of genes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Screening Assays, Antitumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endonucleases

Share to Glutathione S-Transferase pi

Share to National Institutes of Health (U.S.)

Share to Toxicogenetics

Share to United States

Share to Xeroderma Pigmentosum Group D Protein

Source

Identifiers

PMID: 16981845
DOI: 10.2217/14622416.7.6.843

Genes

ERCC2
ERCC5
GSTP1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Relationships between genetic polymorphisms and anticancer drug cytotoxicity vis-à-vis the NCI-60 panel.PMID 16981845Read ↗

Single nucleotide polymorphisms and expression of ERCC1 and ERCC2 vis-à-vis chemotherapy drug cytotoxicity in human glioma.Semantic proximity Read ↗

DNA repair gene polymorphisms affect cytotoxicity in the National Cancer Institute Human Tumour Cell Line Screening Panel.Semantic proximity Read ↗

Impact of EGFR gene polymorphisms on anticancer drug cytotoxicity in vitro.Semantic proximity Read ↗

Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1.Semantic proximity Read ↗

DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.Semantic proximity Read ↗

Pharmacogenomic Characterization of US FDA-approved Cytotoxic DrugsSemantic proximity Read ↗

DNA repair protein levels vis-à-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening programSemantic proximity Read ↗

The association between the T309G polymorphism of the MDM2 gene and sensitivity to anticancer drug is dependent on the p53 mutational status in cellular models.Semantic proximity Read ↗

Discovery of genetic profiles impacting response to chemotherapy: application to gemcitabine.Semantic proximity Read ↗

Application of next generation sequencing to CEPH cell lines to discover variants associated with FDA approved chemotherapeutics.Semantic proximity Read ↗

Genetic variability in cisplatin metabolic pathways and outcome of locally advanced head and neck squamous cell carcinoma patients.Semantic proximity Read ↗

Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.